Charles River Laboratories International
The 10-second takeaway
For the quarter ended Sep. 29 (Q3), Charles River Laboratories International met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue was unchanged and GAAP earnings per share grew significantly.
Margins increased across the board.
Charles River Laboratories International chalked up revenue of $278.7 million. The 14 analysts polled by S&P Capital IQ expected to see a top line of $278.8 million on the same basis. GAAP reported sales were 0.4% higher than the prior-year quarter's $277.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.65. The 18 earnings estimates compiled by S&P Capital IQ predicted $0.62 per share. GAAP EPS of $0.46 for Q3 were 24% higher than the prior-year quarter's $0.37 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 33.5%, 10 basis points better than the prior-year quarter. Operating margin was 13.5%, 10 basis points better than the prior-year quarter. Net margin was 7.9%, 110 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $289.9 million.
Next year's average estimate for revenue is $1.14 billion.
- Add Charles River Laboratories International to My Watchlist.